Concord Biotech drops after Q3 PAT falls 2% YoY to Rs 76 cr
Concord Biotech tumbled 15.02% to Rs 1,793 after the company's consolidated net profit fell 2.1% to Rs 75.92 crore in Q3 FY25 as compared with Rs 77.57 crore in Q3 FY24.
manilatimes20m
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024
Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...
Concord Biotech shares plunge 16% on reporting Q3 results; PAT down 2% YoY
Concord Biotech reported a 2 per cent decline in consolidated net profit to Rs 75.9 crore as compared to Rs 77.6 crore a year ...
The Harvard Crimson45m
As Lab Property Grows Out of Reach for Kendall Square Startups, Many Shift to Leasing Coworking Spaces
The Crimson spoke to a range of commercial realtors, startup founders, and a commercial lab space owner to understand how the immense draw of Kendall Square has forced the myriad startup companies ...
Concord Biotech shares tumble 16% after weak Q3 earnings
Concord Biotech shares fell 16% to Rs 1,777.7 after the company reported a 2.1% YoY decline in Q3 FY25 net profit to Rs 75.92 ...